At-home blood sampling provides convenience and cost savings to patients.
TORRANCE, California (August 16, 2018) – Neoteryx LLC, inventor of Volumetric Absorptive Microsampling (VAMS™) technology, has signed a research agreement with Cedars-Sinai in Los Angeles to initiate a study to find and measure new biomarkers in blood that potentially may predict treatment effectiveness and relapse in patients with inflammatory bowel disease (IBD) – a chronic and recurring immune response and inflammation of the gastrointestinal tract.
Recently, Volumetric Absorptive Microsampling (VAMS™) technology helped a group of organ transplant patients summit Mt. Kilimanjaro. Now students and scientists from the biomedical engineering program at Duke University have found another transformative new use case: testing children in Liberia for biomarkers associated with malnutrition.
Topics: Microsampling in Action